2024’s Biggest Weight Loss Drug Stories
GLP-1s continue to dominate the market, but can pharma keep up with the demand?
Stock.adobe.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Beyond GLP-1s: Q&A with Sandeep Makkar
The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating obesity.
Counterfeit Weight Loss Drugs & Potential Health Risks
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.
The Future of Obesity Pharmacology: Bridging Evidence Gaps with a New Model for Clinical Registries
The challenges in obesity research are significant, but the opportunities for innovation are equally profound.
Experts Weigh-In on Compounded GLP-1/Semaglutide Solution
Industry experts comment on the increasing popularity of compounded medications, particularly GLP-1s, due to drug shortages and the desire for personalized treatments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
